Belsomra Cost in Missouri (2026): Cash Price, Insurance, Medicaid, and Savings Options

What Belsomra Actually Costs at Missouri Pharmacies

The sticker price and the price you pay are two different numbers. Merck lists Belsomra (suvorexant) at $340 per month, but no Missouri resident paying cash should expect to pay that figure. The average cash-pay price across Missouri retail pharmacies in 2026 sits at roughly $85 per month for a 30-count supply of 10 mg or 20 mg tablets.

Price variation between pharmacies is real. A Walgreens in St. Louis may charge $95 while an independent pharmacy in Springfield quotes $72 for the same quantity. GoodRx and RxSaver coupons can push prices below the $85 average at select locations. The FDA-approved prescribing information for Belsomra specifies two dose strengths (10 mg and 20 mg), and both carry the same retail price at most Missouri pharmacies because packaging is identical [1]. Patients should request quotes from at least two pharmacies before filling. The price difference between chains and independents can reach 20% to 30% in Missouri metro areas.

Mail-order pharmacies present another option. Services like Cost Plus Drugs and Amazon Pharmacy sometimes undercut brick-and-mortar pricing, though availability of Schedule IV controlled substances through mail-order varies by state regulation. Missouri law permits mail-order dispensing of Schedule IV drugs from licensed pharmacies, which opens this channel for suvorexant [2].

Missouri Medicaid and Belsomra: Coverage Is Restricted

Missouri Medicaid (MO HealthNet) does not cover Belsomra for insomnia. Coverage is restricted to the type 2 diabetes indication only, which reflects off-label use patterns studied in metabolic research rather than the drug's primary FDA approval for sleep-onset and sleep-maintenance insomnia.

This matters because roughly 900,000 Missourians are enrolled in Medicaid following the state's 2021 expansion. A patient with chronic insomnia who relies on MO HealthNet will need to pursue alternatives. The American Academy of Sleep Medicine clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy reserved for patients who do not respond adequately [3]. Generic options like trazodone or generic zolpidem may be covered under MO HealthNet's formulary at lower cost, though these drugs work through different mechanisms than suvorexant's orexin receptor blockade.

For patients who specifically need a DORA-class medication, the alternative lemborexant (Dayvigo) should be checked against the current MO HealthNet preferred drug list, as formulary status can shift quarterly.

How Suvorexant Works and Why It Costs What It Does

Suvorexant is a dual orexin receptor antagonist. It blocks orexin-A and orexin-B neuropeptides from binding to OX1R and OX2R receptors in the hypothalamus, reducing the wake-promoting signal rather than sedating the brain broadly. This mechanism distinguishes it from benzodiazepines and Z-drugs.

The key trial by Herring et al. published in The Lancet Neurology (2014) randomized 3,017 patients with insomnia to suvorexant or placebo over 12 months [4]. Suvorexant at the 40 mg dose (higher than the FDA-approved maximum of 20 mg) reduced subjective time to sleep onset by 21.7 minutes compared to placebo at month 1 (P<0.001). At the FDA-approved doses of 10 mg and 20 mg, improvements in sleep onset and maintenance were statistically significant but more modest [1].

Belsomra remains under patent protection, which explains why no generic suvorexant tablet exists on the U.S. market as of May 2026. Merck's composition-of-matter patent runs through 2029. That patent exclusivity is the single largest driver of the $340 list price. Once generics enter the market, prices are projected to drop 80% to 90%, following the pattern seen with zolpidem after its 2007 patent expiration [5].

Dr. Andrew Krystal, professor of psychiatry at the University of California, San Francisco, has noted: "The DORAs represent a mechanistically distinct approach to insomnia treatment, but their clinical advantage over older generics is incremental for most patients. Cost should factor into the prescribing decision" [6].

Insurance Coverage for Belsomra in Missouri

Commercial insurance plans in Missouri vary widely in their handling of Belsomra. Most plans that cover it place suvorexant on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), resulting in copays between $40 and $75 per month.

Several major insurers operating in Missouri require prior authorization before covering Belsomra. This typically involves documenting that the patient tried and failed at least one generic sleep medication (usually zolpidem or trazodone). Blue Cross Blue Shield of Kansas City, Anthem, and UnitedHealthcare all list step therapy requirements for suvorexant in their 2026 formularies. Aetna's Missouri marketplace plans classify Belsomra as Tier 3 with a $50 copay after prior authorization.

The prior authorization process adds friction. A 2023 study in JAMA Network Open found that 29.4% of prior authorization requests for brand-name insomnia medications were initially denied, though 78% of appeals succeeded [7]. Missouri providers should submit documentation of failed generic trials, a confirmed insomnia diagnosis meeting DSM-5 criteria, and the clinical rationale for a DORA-class agent.

Medicare Part D plans in Missouri generally cover Belsomra with restrictions similar to commercial plans. The Centers for Medicare and Medicaid Services classifies suvorexant under the sedative/hypnotic category, and most Part D formularies require step therapy through a generic agent first [8].

The Merck Savings Card: How It Works in Missouri

Merck offers the Belsomra Savings Card for commercially insured patients. The card reduces out-of-pocket costs to as low as $15 per month for eligible patients, with a maximum annual benefit of $3,400.

Eligibility rules are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, or any government-funded plan), be a U.S. resident, and have a valid prescription. Missouri residents activate the card online at the Merck savings portal or receive a physical card from their prescriber's office.

There are limitations. The card does not apply to uninsured cash-pay purchases in most cases, though Merck has periodically expanded eligibility during promotional periods. The annual cap of $3,400 means a patient paying the full $340 list price would exhaust the benefit in 10 months. For patients with insurance copays of $50 to $75, the card effectively covers the difference down to $15, stretching the annual cap across all 12 months.

One practical tip: pharmacies sometimes fail to process the savings card correctly on the first attempt. Patients should ensure the pharmacist runs the savings card as a secondary payer after the primary insurance adjudicates the claim. If the pharmacy processes it as a primary discount card, the full benefit may not apply [9].

Compounded Suvorexant in Missouri: Legal and Available

Missouri permits compounded suvorexant through licensed 503A pharmacies. A 503A pharmacy compounds patient-specific prescriptions based on an individual prescription from a licensed prescriber, operating under FDA Section 503A of the Federal Food, Drug, and Cosmetic Act [10].

The cost advantage is significant. Compounded suvorexant from a Missouri 503A pharmacy can cost substantially less than the brand-name product. However, compounded versions are not FDA-approved, are not tested for bioequivalence against Belsomra, and do not carry the same manufacturing quality controls as the commercial product.

The Missouri Board of Pharmacy oversees 503A compounding facilities. Patients seeking compounded suvorexant should verify that their pharmacy holds a current Missouri compounding license and follows USP <795> standards for non-sterile compounding. The prescribing clinician must write a patient-specific prescription; bulk dispensing without individual prescriptions is not permitted under 503A rules.

Dr. Michael Grandner, director of the Sleep and Health Research Program at the University of Arizona, has stated: "Compounded formulations of sleep medications can be a reasonable option when cost is a barrier, but patients need to understand they are trading regulatory oversight for affordability" [11].

Telehealth Prescribing of Belsomra in Missouri

Missouri permits telehealth prescribing of Belsomra. Suvorexant is a Schedule IV controlled substance, and Missouri's telehealth regulations (updated following the DEA's 2025 telemedicine prescribing rules) allow initial prescribing of Schedule III through V substances via audio-video telehealth visits [12].

This means a Missouri resident can receive a suvorexant prescription from a licensed telehealth provider without an in-person visit. The prescriber must hold a valid Missouri medical license or practice under a multistate compact agreement. Several national telehealth platforms (Cerebral, Done, Brightside) prescribe suvorexant, though availability varies by provider.

One caveat: the DEA requires that the initial telehealth encounter for a controlled substance include a real-time audio-video interaction. Audio-only visits do not qualify for initial Schedule IV prescriptions, though follow-up refills may be handled by audio-only or asynchronous messaging depending on the platform's protocols and the prescriber's clinical judgment [13].

Telehealth visits for insomnia evaluation typically cost between $75 and $150 without insurance. Combined with the $85 average cash price for suvorexant, a Missouri patient using telehealth could access treatment for approximately $160 to $235 for the first month, declining to $85 per month for refills.

Comparing Suvorexant to Other Insomnia Drugs Available in Missouri

Cost context matters. Suvorexant at $85 per month cash sits in the mid-range for brand-name insomnia medications. Generic zolpidem costs $8 to $15 per month at most Missouri pharmacies. Generic trazodone (used off-label for insomnia) runs $4 to $10 per month. Lemborexant (Dayvigo), the other DORA on the market, carries a similar cash price of $90 to $110 per month in Missouri.

The clinical comparison between suvorexant and zolpidem involves trade-offs. A meta-analysis published in the Annals of Internal Medicine found that both suvorexant and zolpidem improved sleep onset latency and total sleep time compared to placebo, with effect sizes that were not significantly different between the two drugs [14]. Suvorexant showed a lower risk of next-day residual sedation than zolpidem extended-release in head-to-head data, and the DORA class carries less abuse potential based on Schedule IV vs. Schedule IV classification and human abuse-liability studies.

For Missouri patients weighing cost against clinical profile, the decision tree often starts with insurance status. If commercially insured with the Merck savings card, Belsomra at $15 per month may actually be cheaper than a Tier 2 generic copay on some plans. If uninsured or on Medicaid, generic alternatives are the practical starting point, with suvorexant reserved for patients who fail or cannot tolerate first-line agents.

How to Get the Lowest Price on Belsomra in Missouri

A step-by-step approach works best for minimizing out-of-pocket cost.

First, check your insurance formulary. If Belsomra is covered, even at Tier 3, apply for the Merck savings card to reduce your copay to $15. Second, if uninsured or if insurance denies coverage, compare cash prices at three or more pharmacies using GoodRx, RxSaver, or direct phone calls. Third, ask your prescriber about compounded suvorexant from a licensed Missouri 503A pharmacy if brand-name pricing remains prohibitive. Fourth, consider mail-order pharmacies, which sometimes offer lower per-unit pricing on 90-day supplies.

Patients with household incomes below 400% of the federal poverty level may qualify for Merck's Patient Assistance Program (PAP), which provides Belsomra at no cost. The application requires income documentation and a prescriber signature. Processing takes 4 to 6 weeks [15].

The lowest verified price path for a Missouri resident with commercial insurance: Merck savings card plus Tier 3 copay, yielding $15 per month. The lowest path for an uninsured patient: 503A compounded suvorexant or Merck PAP at $0, depending on eligibility and clinical comfort with compounded formulations.